Biobank of tissue, blood, stool, and clinical data associated for research purposes on primary cancers and lung metastases, Canada

Certification Status: Approved

Registration Status: Completed

Objective: Lung cancer is the leading cause of cancer death worldwide. In fact, lung cancer is responsible for 1.59 million deaths annually, despite the treatments currently available. Researchers interested in this area are working to improve current knowledge, treatment and patient care. The purpose of this biobank is to enable researchers to use banked tissue, blood, and stool samples as well as their corresponding clinical data to carry out lung tumor research projects to better understand pathologies and improve overall healthcare of patients who suffer from it. In addition, researchers will try to better understand the link between the microbiota (all bacteria present in your digestive tract) and the response to cancer treatments. On the other hand, this biobank could be used for teaching purposes or evaluation of clinical practices.

Registered Biobank Name	Biobank of tissue, blood, stool, and clinical data associated for research purposes on primary cancers and lung metastases
Biobank Leader	Meriem Messaoudene
Country	Canada
Email for biobank inquiries	meriem.messaoudene@umontreal.ca
Principal Investigator	Bertrand Routy
Website
User Type Mono: A biobank that supports a specific research project, may have few staff members, a small-scale accrual scope with little to no initial intention of releasing or distributing biospecimens to secondary parties Oligo: A biobank that supports several research groups or clinical trials, may or may not be designed to release biospecimens outside their collaborative group Poly: A biobank that has generally a larger accrual scope, resources, and multiple users outside the biobank proper	Mono - Collection aimed at supporting a specific, single research project

Biospecimen Collected:

Cohort Highlights

100 cases Next Generation Sequencing assay to detect all classes of genetic variant in Lung Cancer using a single Diagnostic test.
200 cases Colorectal TMA for QC purposes in support of study of tumor infiltrating lymphocytes in ovarian cancer tissues.
Build 300 cases breast cancer TMA containing primary tumour and matched metastatic LN for various subtypes (luminal, HER2, Triple negative). Start with Triple negatives.
125 cases Breast tumour and metastatic lymph nodes in breast cancer cases with outcomes of metastasis to lung or bone.
100 cases of rare tumours - fibrolamellar hepatocellular carcinoma. FFPE, frozen, BC.
200 cases of FFPE tissue sections from breast, lung adenocarcinoma, and lung squamous cell carcinoma with matching normal tissue (only pathology data requested).